Logo image of TSBX

TURNSTONE BIOLOGICS CORP (TSBX) Stock Fundamental Analysis

NASDAQ:TSBX - Nasdaq - US90042W1009 - Common Stock - Currency: USD

0.3886  -0.02 (-4.4%)

After market: 0.3777 -0.01 (-2.8%)

Fundamental Rating

2

Overall TSBX gets a fundamental rating of 2 out of 10. We evaluated TSBX against 571 industry peers in the Biotechnology industry. The financial health of TSBX is average, but there are quite some concerns on its profitability. TSBX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TSBX has reported negative net income.
TSBX had a negative operating cash flow in the past year.
TSBX Yearly Net Income VS EBIT VS OCF VS FCFTSBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 20M -20M -40M -60M

1.2 Ratios

TSBX's Return On Assets of -127.24% is on the low side compared to the rest of the industry. TSBX is outperformed by 81.53% of its industry peers.
TSBX's Return On Equity of -170.52% is on the low side compared to the rest of the industry. TSBX is outperformed by 67.14% of its industry peers.
Industry RankSector Rank
ROA -127.24%
ROE -170.52%
ROIC N/A
ROA(3y)-24.7%
ROA(5y)N/A
ROE(3y)-32.05%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TSBX Yearly ROA, ROE, ROICTSBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 -20 -40

1.3 Margins

TSBX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TSBX Yearly Profit, Operating, Gross MarginsTSBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 0 -100 -200 -300

More info and screens

6

2. Health

2.1 Basic Checks

TSBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TSBX has been increased compared to 1 year ago.
TSBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TSBX Yearly Shares OutstandingTSBX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 50M 100M
TSBX Yearly Total Debt VS Total AssetsTSBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M 150M

2.2 Solvency

TSBX has an Altman-Z score of -8.93. This is a bad value and indicates that TSBX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.93, TSBX is doing worse than 71.58% of the companies in the same industry.
There is no outstanding debt for TSBX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.93
ROIC/WACCN/A
WACC9.44%
TSBX Yearly LT Debt VS Equity VS FCFTSBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M -50M

2.3 Liquidity

TSBX has a Current Ratio of 3.75. This indicates that TSBX is financially healthy and has no problem in meeting its short term obligations.
TSBX has a Current ratio (3.75) which is in line with its industry peers.
TSBX has a Quick Ratio of 3.75. This indicates that TSBX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of TSBX (3.75) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.75
Quick Ratio 3.75
TSBX Yearly Current Assets VS Current LiabilitesTSBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.89% over the past year.
Looking at the last year, TSBX shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)3.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 24.81% on average over the next years. This is a very strong growth
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y44.38%
EPS Next 2Y37.32%
EPS Next 3Y24.81%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

TSBX Yearly Revenue VS EstimatesTSBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
TSBX Yearly EPS VS EstimatesTSBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TSBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TSBX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TSBX Price Earnings VS Forward Price EarningsTSBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TSBX Per share dataTSBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as TSBX's earnings are expected to grow with 24.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.32%
EPS Next 3Y24.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TSBX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TURNSTONE BIOLOGICS CORP

NASDAQ:TSBX (2/21/2025, 8:00:01 PM)

After market: 0.3777 -0.01 (-2.8%)

0.3886

-0.02 (-4.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners52.12%
Inst Owner Change9.32%
Ins Owners3.83%
Ins Owner ChangeN/A
Market Cap8.99M
Analysts47.5
Price Target2.47 (535.62%)
Short Float %2.65%
Short Ratio2.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.33%
Min EPS beat(2)3.01%
Max EPS beat(2)15.64%
EPS beat(4)3
Avg EPS beat(4)7.06%
Min EPS beat(4)-7.53%
Max EPS beat(4)17.1%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-29.27%
EPS NQ rev (1m)10%
EPS NQ rev (3m)8.57%
EPS NY rev (1m)3.57%
EPS NY rev (3m)6.41%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.21
P/tB 0.21
EV/EBITDA N/A
EPS(TTM)-3.24
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-2.88
FCFYN/A
OCF(TTM)-2.87
OCFYN/A
SpS0
BVpS1.89
TBVpS1.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -127.24%
ROE -170.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.7%
ROA(5y)N/A
ROE(3y)-32.05%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.5%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.75
Quick Ratio 3.75
Altman-Z -8.93
F-Score3
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)140.74%
Cap/Depr(5y)N/A
Cap/Sales(3y)5.63%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26%
EPS Next Y44.38%
EPS Next 2Y37.32%
EPS Next 3Y24.81%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-8.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.98%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.91%
OCF growth 3YN/A
OCF growth 5YN/A